Trisenox and blood alkaline phosphatase increased Patient Reports February 09, 2010

Trisenox Side Effects Report #4855373-2
Trisenox side effect was reported by a Health Professional from UNITED STATES on May 31, 2005. Male patient, 79 years of age, was diagnosed with myelodysplastic syndrome and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased. Trisenox dosage: 19 MG (0.25 MG/KG, 5 DOSE LOAD), IVI. During the same period patient was treated with CHLOROQUINE PHOSPHATE, DEMADEX, OXYCODONE, DESYREL, ARANESP, MEPROBAMATE, POTASSIUM, ALLOPURINOL. Patient recovered.

Trisenox Side Effects Report #4735806-2
Trisenox side effect was reported by a Physician from UNITED STATES on July 18, 2005. Male patient, weighting 191.8 lb, was diagnosed with myelodysplastic syndrome and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, blood alkaline phosphatase increased, blood glucose increased, diarrhoea. Trisenox dosage: 15 MG (15 MG, BIW), IVI. During the same period patient was treated with ASCORBIC ACID. Patient recovered.

Trisenox Side Effects Report #5536194-4
Trisenox side effect was reported by a Physician from JAPAN on Nov 20, 2007. Male patient, 88 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood albumin decreased, blood alkaline phosphatase increased, c-reactive protein increased, electrocardiogram qt prolonged, fluid retention, gamma-glutamyltransferase increased, hepatic function abnormal. Trisenox dosage: 7.05 MG QD INTRAVENOUS DRIP. During the same period patient was treated with SULFAMETHOXAZOLE AND TRIMETHOPRIM, POLYMYXIN B SULPHATE. Patient recovered.

Trisenox Side Effects Report #4609439-2
Trisenox side effect was reported by a Physician from on Feb 21, 2005. Female patient, 72 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, condition aggravated, gamma-glutamyltransferase increased, hepatic function abnormal. Trisenox dosage: unknown. Patient recovered.


Trisenox Side Effects Report #4618289-2
Trisenox side effect was reported by a Physician from on Mar 02, 2005. Female patient, 72 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: acute myeloid leukaemia, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, condition aggravated, gamma-glutamyltransferase increased, haemoglobin decreased, hepatic function abnormal. Trisenox dosage: unknown. Patient recovered.

Trisenox Side Effects Report #4675632-6
Trisenox side effect was reported by a Physician from on Feb 14, 2005. Female patient, 72 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, gamma-glutamyltransferase increased, hepatic function abnormal. Trisenox dosage: 4.8 MG (4.8 MG,), INTRAVENOUS. Patient recovered.

Trisenox Side Effects Report #4686792-5
Trisenox side effect was reported by a Physician from on May 08, 2005. Female patient, 72 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, gamma-glutamyltransferase increased, haemoglobin decreased, hepatic function abnormal. Trisenox dosage: 4.8 MG (4.8 MG) INTRAVENOUS. Patient recovered.

Trisenox Side Effects Report #4781090-3
Trisenox side effect was reported by a Physician from JAPAN on Sept 07, 2005. Male patient, 72 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, condition aggravated, gamma-glutamyltransferase increased, hepatic function abnormal, hypokalaemia. Trisenox dosage: 6 MG (6 MG, IVI). During the same period patient was treated with BIAPENEM, VANCOMYCIN, CLINDAMYCIN, CEFTAZIDIME, ALLOPURINOL, TOSUFOXACIN, FLUCONAZOLE, FAMOTIDINE. Patient recovered.

Trisenox Side Effects Report #5248065-1
Trisenox side effect was reported by a Physician from JAPAN on Feb 06, 2007. Male patient, 67 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood alkaline phosphatase increased, catheter related infection, electrocardiogram qt prolonged, gamma-glutamyltransferase increased, hyperglycaemia, pathogen resistance, staphylococcal infection . Trisenox dosage: 9.69 MG Q1D INTRAVENOUS DRIP. During the same period patient was treated with DALTEPARIN, METHYLPHENIDATE, ALPRAZOLAM, MILNACIPRAN HYDROCHLORIDE, AMIKACIN SULPHATE, PAROXETINE HYDROCHLORIDE. Patient recovered.


Trisenox Side Effects Report #5306139-0
Trisenox side effect was reported by a Physician from JAPAN on Apr 02, 2007. Male patient, 67 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood alkaline phosphatase increased, cardio-respiratory arrest, electrocardiogram qt prolonged, febrile neutropenia, gamma-glutamyltransferase increased, hyperglycaemia, staphylococcal sepsis. Trisenox dosage: 9.69 MG QD INTRAVENOUS DRIP. During the same period patient was treated with DALTEPARIN, QUETIAPINE FUMARATE, VANCOMYCIN HYDROCHLORIDE, CEFEPIME DIHYDROCHLORIDE, METHYLPHENIDATE, PAROXETINE. Patient died on 01/19/2006.

Trisenox Side Effects Report #5390810-9
Trisenox side effect was reported by a Physician from JAPAN on July 06, 2007. Male patient, 67 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood alkaline phosphatase increased, catheter related infection, electrocardiogram qt prolonged, gamma-glutamyltransferase increased, hyperglycaemia, staphylococcal infection . Trisenox dosage: 9.69 MG QD INTRAVENOUS DRIP. During the same period patient was treated with DALTEPARIN, METHYLPHENIDATE, ALPRAZOLAM, MILNACIPRAN HYDROCHLORIDE, AMIKACIN SULPHATE, PAROXETINE HYDROCHLORIDE HYDRATE. Patient recovered.

Trisenox Side Effects Report #5393083-6
Trisenox side effect was reported by a Physician from JAPAN on June 27, 2007. Male patient, 67 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood alkaline phosphatase increased, blood lactate dehydrogenase increased, cardio-respiratory arrest, electrocardiogram qt prolonged, febrile neutropenia, gamma-glutamyltransferase increased, hyperglycaemia, staphylococcal sepsis. Trisenox dosage: 9.69 MG QD INTRAVENOUS DRIP. During the same period patient was treated with DALTEPARIN, QUETIAPINE FUMARATE, VANCOMYCIN HYDROCHLORIDE, CEFEPIME DIHYDROCHLORIDE, METHYLPHENIDATE, PAROXETINE HYDROCHLORIDE HYDRATE. Patient died on 01/19/2006.

Trisenox Side Effects Report #5047198-2
Trisenox side effect was reported by a Physician from JAPAN on June 23, 2006. Male patient, 64 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, electrocardiogram qt prolonged, gamma-glutamyltransferase increased. Trisenox dosage: 8.76 MG QD INTRAVENOUS DRIP. During the same period patient was treated with CYTARABINE, IDARUBICIN, MEXILETINE HYDROCHLORIDE, GABEXATE MESILATE, AMIKACIN SULPHATE. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #4701616-5
Trisenox side effect was reported by a Physician from on June 07, 2005. Male patient, 64 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, electrocardiogram qt prolonged. Trisenox dosage: 8.76 MG (8.76 MILLICURIES), IVI. During the same period patient was treated with MEXILETINE. Patient was hospitalized. Patient recovered.


Trisenox Side Effects Report #4831873-6
Trisenox side effect was reported by a Physician from JAPAN on Nov 01, 2005. Male patient, 64 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, electrocardiogram qt corrected interval prolonged, electrocardiogram qt prolonged. Trisenox dosage: 8.76 MG QD INTRAVENOUS. During the same period patient was treated with MEXILETINE HYDROCHLORIDE. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #4938437-4
Trisenox side effect was reported by a Physician from JAPAN on Feb 21, 2006. Male patient, 64 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, electrocardiogram qt corrected interval prolonged, gamma-glutamyltransferase increased, hepatic function abnormal. Trisenox dosage: 8.76 MG QD INTRAVENOUS. During the same period patient was treated with MEXILETINE HYDROCHLORIDE, CYTARABINE, GABEXATE MESILATE, AMIKACIN SULPHATE. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5680028-4
Trisenox side effect was reported by a Physician from JAPAN on Mar 12, 2008. Male patient, 63 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, acute promyelocytic leukaemia, alanine aminotransferase increased, aspartate aminotransferase increased, blood albumin decreased, blood alkaline phosphatase increased, blood bilirubin increased, blood calcium decreased, blood lactate dehydrogenase increased. Trisenox dosage: K9.75 MG QD; INTRAVENOUS. During the same period patient was treated with ARBEKACIN SULPHATE, MEROPENEM, MEXILETINE HYDROCHLORIDE, DALTEPARIN, HYDROCORTISONE SUCCINATE, RANITIDINE HYDROCHLORIDE, ALLOPURINOL. Patient was hospitalized. Patient died on 05/10/2007.

Trisenox Side Effects Report #5701452-7
Trisenox side effect was reported by a Physician from JAPAN on Mar 24, 2008. Male patient, 63 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, acute promyelocytic leukaemia, alanine aminotransferase increased, aspartate aminotransferase increased, blood albumin decreased, blood alkaline phosphatase increased, blood bilirubin increased, blood calcium decreased, blood creatinine increased. Trisenox dosage: 9.75 MG, QD; INTRAVENOUS. During the same period patient was treated with ARBEKACIN SULPHATE, MEROPENEM TRIHYDRATE, MEROPENEM TRIHYDRATE, MEXILETINE HYDROCHLORIDE, DALTEPARIN, HYDROCORTISONE SUCCINATE, RANITIDINE HYDROCHLORIDE. Patient was hospitalized. Patient died on 05/08/2007.

Trisenox Side Effects Report #5724215-5
Trisenox side effect was reported by a Physician from JAPAN on Apr 14, 2008. Female patient, 61 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, gamma-glutamyltransferase increased, hepatic function abnormal. Trisenox dosage: 8.175 MG, QD; INTRAVENOUS DRIP. During the same period patient was treated with POLYMYXIN B SULPHATE, SULFAMETHOXAZOLE AND TRIMETHOPRIM. Patient recovered.


Trisenox Side Effects Report #5408384-2
Trisenox side effect was reported by a Physician from JAPAN on July 25, 2007. Female patient, 58 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, back disorder, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, bone pain, disseminated intravascular coagulation, electrocardiogram qt prolonged, gamma-glutamyltransferase increased. Trisenox dosage: 7.245 MG QD INTRAVENOUS DRIP. During the same period patient was treated with IDARUBICIN, NAFAMOSTAT MESILATE, GLUCOSE W, ELECTROLYTE, PARENTERAL FLUID OF HIGH, INSULIN. Patient recovered.

Trisenox Side Effects Report #5266132-3
Trisenox side effect was reported by a Physician from JAPAN on Feb 27, 2007. Female patient, 57 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: acute promyelocytic leukaemia differentiation syndrome, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood lactate dehydrogenase increased, c-reactive protein increased, condition aggravated, disseminated intravascular coagulation. Trisenox dosage: unknown. During the same period patient was treated with CYTARABINE, IDARUBICIN, DANAPAROID, CARBAZOCHROME SULFONATE, TRANEXAMIC ACID, MONOAMMONIUM GLYCYRRHIZINATE. Patient died on 12/31/2006.

Trisenox Side Effects Report #4701607-4
Trisenox side effect was reported by a Physician from on June 07, 2005. Female patient, 54 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood albumin decreased, blood alkaline phosphatase increased, blood urea decreased, electrocardiogram qt prolonged, hyperglycaemia, pancytopenia, protein total decreased. Trisenox dosage: 5.67 MG (5.67 MG, QD), IVI. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5292474-1
Trisenox side effect was reported by a Physician from JAPAN on Mar 20, 2007. Male patient, 51 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: acute promyelocytic leukaemia, blood alkaline phosphatase increased, blood potassium decreased, blood urea increased, electrocardiogram qt prolonged, malaise, malignant neoplasm progression, renal impairment, sepsis . Trisenox dosage: 9.165 MG QD INTRAVENOUS DRIP. During the same period patient was treated with AMPHOTERICIN N, CEFTAZIDIME, MICAFUNGIN, IDARUBICIN, CYTARABINE, DALTEPARIN, ISEPAMICIN SULPHATE. Patient was hospitalized. Patient died on 04/18/2006.

Trisenox Side Effects Report #5844627-9
Trisenox side effect was reported by a Physician from JAPAN on July 28, 2008. Male patient, 49 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood albumin decreased, blood alkaline phosphatase increased, blood calcium decreased, blood cholesterol decreased, blood creatine phosphokinase decreased, blood sodium decreased, disseminated intravascular coagulation, electrocardiogram qt prolonged, hyperglycaemia. Trisenox dosage: 9.15 MG DAILY INTRAVENOUS DRIP. During the same period patient was treated with MAGNESIUM SULPHATE, CALCIUM, GABEXATE MESILATE, HYDROCORTISONE SUCCINATE, TOBRAMYCIN, CIPROFLOXACIN, MEROPENEM TRIHYDRATE, HALOPERIDOL. Patient was hospitalized. Patient recovered.


Trisenox Side Effects Report #5886835-7
Trisenox side effect was reported by a Physician from JAPAN on Sept 03, 2008. Male patient, 49 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood albumin decreased, blood alkaline phosphatase increased, blood calcium decreased, blood cholesterol decreased, blood creatine phosphokinase decreased, blood sodium decreased, disseminated intravascular coagulation, electrocardiogram qt prolonged, hyperglycaemia. Trisenox dosage: 9.15 MG DAILY INTRAVENOUS DRIP. During the same period patient was treated with MAGNESIUM SULPHATE, CALCIUM GLUCONATE, GABEXATE MESILATE, HYDROCORTISONE SUCCINATE, TOBRAMYCIN, CIPROFLOXACIN, MEROPENEM TRIHYDRATE, HALOPERIDOL. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #6115919-3
Trisenox side effect was reported by a Physician from JAPAN on Feb 26, 2009. Male patient, 48 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood albumin decreased, blood alkaline phosphatase increased, blood calcium decreased, blood cholesterol decreased, blood creatine phosphokinase decreased, blood sodium decreased, colon cancer, disseminated intravascular coagulation, electrocardiogram qt prolonged. Trisenox dosage: 9.15 MG DAILY INTRAVENOUS DRIP. During the same period patient was treated with MAGNESIUM SULPHATE, CALCIUM, GABEXATE MESILATE, HYDROCORTISONE SUCCINATE, TOBRAMYCIN, CIPROFLOXACIN, MEROPENEM TRIHYDRATE, HALOPERIDOL. Patient was hospitalized. Patient died on 08/27/2007.

Trisenox Side Effects Report #6121941-3
Trisenox side effect was reported by a Physician from JAPAN on Feb 26, 2009. Male patient, 48 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood albumin decreased, blood alkaline phosphatase increased, blood calcium decreased, blood cholesterol decreased, blood creatine phosphokinase decreased, blood sodium decreased, disseminated intravascular coagulation, electrocardiogram qt prolonged, hyperglycaemia. Trisenox dosage: unknown. During the same period patient was treated with MAGNESIUM SULPHATE, CALCIUM, GABEXATE MESILATE, HYDROCORTISONE SUCCINATE, TOBRAMYCIN, CIPROFLOXACIN, MEROPENEM, HALOPERIDOL. Patient was hospitalized. Patient died on 08/27/2007.

Trisenox Side Effects Report #6088508-7
Trisenox side effect was reported by a Physician from JAPAN on Feb 09, 2009. Male patient, 46 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, blood alkaline phosphatase increased, haemoglobin decreased, hepatic function abnormal, platelet count decreased, white blood cell count decreased. Trisenox dosage: 7.65 MG QD; INTRAVENOUS DRIP. During the same period patient was treated with CYTARABINE, METHOTREXATE, DEXAMETHASONE PHOSPHATE, FILGRASTIM. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #6108579-9
Trisenox side effect was reported by a Health Professional from JAPAN on Feb 19, 2009. Male patient, 46 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, blood alkaline phosphatase increased, haemoglobin decreased, hepatic function abnormal, platelet count decreased, white blood cell count decreased. Trisenox dosage: 7.65 MG QD INTRAVENOUS DRIP. During the same period patient was treated with CYTARABINE, METHOTREXATE, DEXAMETHASONE PHOSPHATE, FILGRASTIM. Patient was hospitalized and became disabled. Patient recovered.